Mon, July 18, 2022
Sat, July 16, 2022
Fri, July 15, 2022
Thu, July 14, 2022

Matthew Harrison Maintained (BNTX) at Hold with Decreased Target to $194 on, Jul 15th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-decreased-target-to-194-on-jul-15th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Harrison of Morgan Stanley, Maintained "BioNTech SE" (BNTX) at Hold with Decreased Target from $195 to $194 on, Jul 15th, 2022.

Matthew has made no other calls on BNTX in the last 4 months.



There are 6 other peers that have a rating on BNTX. Out of the 6 peers that are also analyzing BNTX, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Emmanuel Papadakis of "Deutsche Bank" Maintained at Hold and Held Target at $180 on, Wednesday, June 1st, 2022
  • Chris Shibutani of "Goldman Sachs" Maintained at Hold with Decreased Target to $206 on, Tuesday, May 24th, 2022


These are the ratings of the 4 analyists that currently disagree with Matthew


  • Daina Graybosch of "SVB Leerink" Upgraded from Hold to Buy and Decreased Target to $223 on, Wednesday, July 13th, 2022
  • Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $283 on, Monday, July 11th, 2022
  • William Maughan of "Canaccord Genuity" Initiated at Strong Buy and Held Target at $192 on, Wednesday, July 6th, 2022
  • Arlinda Lee of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $300 on, Tuesday, April 5th, 2022

Publication Contributing Sources